Advertisement

Breast Cancer Research and Treatment

, Volume 156, Issue 3, pp 567–576 | Cite as

Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls

  • Kathy Pan
  • Rowan T. ChlebowskiEmail author
  • Michael S. Simon
  • Roberta M. Ray
  • Jennifer Livaudais-Toman
  • Shannon D. Sullivan
  • Marcia L. Stefanick
  • Robert B. Wallace
  • Meryl LeBoff
  • Elizabeth Carhart Bluhm
  • Electra D. Paskett
Epidemiology

Abstract

While adverse medical sequelae are associated with breast cancer therapies, information on breast cancer impact on medication use is limited. Therefore, we compared medication use before and after diagnosis of early stage breast cancer to medication use in matched, cancer-free controls. Of 68,132 Women’s Health Initiative participants, 3726 were diagnosed with breast cancer and, after exclusions, in 1731 breast cancer cases, medication use before and >3 years after diagnosis (mean 5.3 ± 2.1 SD) was compared to use in 1731 cancer-free matched controls on similar inventory dates. The medication category number at follow-up inventory was the primary study outcome. Medication category use (n, mean, SD) was comparable at baseline and significantly increased at follow-up in both cases (2.48 ± 1.66 vs. 4.15 ± 2.13, baseline vs follow-up, respectively, P < .0001) and controls (2.44 ± 1.67 vs. 3.95 ± 2.13, respectively, P < .0001), with clinically marginal but statistically significant additional medication category use by cases (0.20 ± 2.40, P < .0001). Tamoxifen users used somewhat more selected medication categories at follow-up assessment (mean 3.40 ± 1.89 vs. 3.21 ± 1.99, respectively, P = 0.05), while aromatase inhibitor users used more medication categories (mean 4.85 ± 2.10 vs. 4.44 ± 1.94, respectively, P = 0.02). No increase in medication category was seen in cases who were not current endocrine therapy users. Breast cancer survivors having only a clinically marginal increase in medication use compared to cancer-free controls. These findings highlight the importance of incorporation of control populations in studies of cancer survivorship.

Keywords

Breast cancer Medication Survivorship Control group Women’s Health Initiative Comorbidity 

Notes

Funding

The WHI program is reported by the National Heart, Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221.

Role of the sponsor

The WHI Project Office at the US National Heart, Lung, and Blood Institute (NHLBI) reviewed and approved the final manuscript but had no other role in the preparation of this report.

Author contributions

KP and RTC wrote the analysis proposal and initial draft of the report. KP and RTC had full access to the data in the study and take full responsibility for the integrity of the data and the accuracy of the data analysis. RR undertook the statistical analysis. RTC, JEM, MLS, MSS, KCJ, JW, MJO, and RLP collected the data and obtained study funding. Additional contributions: We thank the Women’s Health Initiative investigators, staff, and the trial participants for their outstanding dedication and commitment.

Women’s Health Initiative investigators

Program office (National Heart, Lung, and Blood Institute, Bethesda, MD) Jacques Roscoe, Shari Ludlum, Dale Burden, Joan McGowan, Leslie Ford, and Nancy Geller. Clinical coordinating center (Fred Hutchinson Cancer Research Center, Seattle, WA) Garnet Anderson, Ross Prentice, Andrea LaCroix, and Charles Kooperberg. Investigators and academic centers (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA) JoAnn E, Manson; (MedStar Health Research Institute/Howard University, Washington, DC) Barbara V Howard; (Stanford Prevention Research Center, Stanford, CA) Marcia L. Stefanick; (The Ohio State University, Columbus, OH) Rebecca Jackson; (University of Arizona, Tucson/Phoenix, AZ) Cynthia A. Thompson; (University at Buffalo, Buffalo, NY) Jean Wactawski-Wende; (University of Florida, Gainesville/Jacksonville, FL) Marian Limacher; (University of Iowa, Iowa City/Davenport, IA) Robert Wallace; (University of Pittsburgh, Pittsburgh, PA) Lewis Kuller; (Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA) Rowan T. Chlebowski; (Wake Forest University School of Medicine, Winston Salem, NC) Sally Shumaker. Women’s Health Initiative memory study (Wake Forest University School of Medicine, Winston Salem, NC) Sally Shumaker. Additional information A full list of all the investigators who have contributed to Women’s Health Initiative science appears at https://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Long%20List.pdf.

Compliance with ethical standards

Conflict of interest

All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Chlebowski reported being a consultant for AstraZenea, Novartis, Amgen, Genomic Health and Novo Nordisk, receiving funding support from Amgen, and serving on the speaker’s bureau for Novartis and Genentech.

Supplementary material

10549_2016_3773_MOESM1_ESM.docx (16 kb)
Supplementary material 1 (DOCX 16 kb)

References

  1. 1.
    Howlader N, Noone AM, Krapcho M et al (2012) SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2010/. based on November 2012 SEER data submission, posted to the SEER web site, 2013
  2. 2.
    Ganz PA, Hahn EE (2008) Implementing a survivorship care plan for patients with breast cancer. J Clin Oncol 26:759–767CrossRefPubMedGoogle Scholar
  3. 3.
    Jassim GA, Whitford DL, Hickey A et al (2015) Psychological interventions for women with non-metastatic breast cancer. Cochrance Database Syst Rev 25(5):CD008729. doi: 10.1002/14651858.CD008729.pub2 Google Scholar
  4. 4.
    Chlebowski R, Cuzick J, Amakye D et al (2009) Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 2:S1–S11CrossRefGoogle Scholar
  5. 5.
    Eastell R, Adams J, Clack G et al (2011) Long-term effects of anastrozole on bone mineral density: seven-year results from the ATAC trial. Ann Oncol 22:857–862CrossRefPubMedGoogle Scholar
  6. 6.
    Freedman AN, Yu B, Gail MH et al (2011) Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 29:2327–2333CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ganz PA, Desmond KA, Leedham B et al (2002) Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 94:39–49CrossRefPubMedGoogle Scholar
  8. 8.
    Kwan KW, Chlebowski RT (2009) Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer. Clin Breast Cancer 9:219–224CrossRefPubMedGoogle Scholar
  9. 9.
    Eisner A, Luoh SW (2011) Breast cancer medications and vision: effects of treatments for early stage disease. Curr Eye Res 36:867–885CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Aiello Bowles EJ, Wellman R, Feigelson HS et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104:1293–1305CrossRefGoogle Scholar
  11. 11.
    Hayes DF (2007) Follow-up of patients with early breast cancer. N Engl J Med 356:2505–2513CrossRefPubMedGoogle Scholar
  12. 12.
    Lenihan DJ, Cardinale DM (2012) Late cardiac effects of cancer treatment. J Clin Oncol 30:3657–3664CrossRefPubMedGoogle Scholar
  13. 13.
    Gartner R, Jensen MB, Nielsen J et al (2009) Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 302:1985–1992CrossRefPubMedGoogle Scholar
  14. 14.
    De Iuliis F, Taglieri L, Salerno G et al (2015) Taxane induced neuropathy in patients affected by breast cancer: literature review. Crit Rev Oncol Hematol 96:34–45. doi: 10.1016/j.critrevonc.2015.04.011 CrossRefPubMedGoogle Scholar
  15. 15.
    Erven K, Weltens C, Nackaerts K et al (2012) Changes in pulmonary function up to 10 years after locoregional breast irradiation. Int J Radiat Oncol Niol Phys 82:701–707CrossRefGoogle Scholar
  16. 16.
    Ricceri F, Fasanelli F, Giraudo MT et al (2015) Risk of second primary malignancies in women with breast cancer: results from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 137:940–948CrossRefPubMedGoogle Scholar
  17. 17.
    Majkowska-Mlynarczyk A, Kinalski M, Zaczek-Kucharska E (2007) The thyroid gland function assessment in women after mastectomy and chemotherapy during breast cancer therapy. Endokrynol Pol 58:397–402PubMedGoogle Scholar
  18. 18.
    Edwards BK, Noone AM, Mariotto AB et al (2014) Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 120(9):1290–1314CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Jordan JH, Thwin SS, Lash TL et al (2014) Incident comorbidities and all-cause mortality among 5-year survivors of stage I and II breast cancer diagnosed at age 565 or older: a prospective-matched cohort study. Breast Cancer Res Treat 146(2):401–409CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Otte JL, Skaar TC, WU J et al (2013) Medication use in breast cancer survivors compared to midlife women. Support Care Cancer 21:1827–1833CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Ridner SH, Dietrich MS (2008) Self-reported comorbid conditions and medication usage in breast cancer survivors with and without lymphedema. Oncol Nurs Forum 35:57–63CrossRefPubMedGoogle Scholar
  22. 22.
    Anderson GL, Manson J, Wallace R et al (2003) Implementation of the Women’s Health Initiative study design. Am Epidemiol 13(9):S5–S17CrossRefGoogle Scholar
  23. 23.
    Curb JD, McTiernan A, Heckbert SR et al (2003) Outcomes ascertainment and adjudication methods in the Women’s Health Initiative. Ann Epidemiol 13:S122–S128CrossRefPubMedGoogle Scholar
  24. 24.
    National Cancer Institute: Surveillance, epidemiology, and end results program. http://seer.cancer.gov/. Accessed 1 July 2015
  25. 25.
    Harlan LC, Klabunde CN, Ambs AH et al (2009) Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer. J Cancer Surviv 3:89–98CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Bower JE, Bak K, Berger A et al (2014) Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology Clinical Practice Guideline Adaptation. J Clin Oncol 32:1840–1850CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hershman DL, Lacchetti C, Dworkin RH et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guidelines. J Clin Oncol 32:1941–1967CrossRefPubMedGoogle Scholar
  28. 28.
    Anderson BL, DuRubeis RJ, Berman BS et al (2014) Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology Clinical Practice Guideline Adaptation. J Clin Oncol 32:1605–1619CrossRefGoogle Scholar
  29. 29.
    Bernhard J, Luo W, Ribi K et al (2015) Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. doi: 10.1016/S1470-2045(15)00049-2 PubMedGoogle Scholar
  30. 30.
    Chlebowski RT (2015) Interpreting quality of life data from the SOFT and TEXT trials. Lancet Oncol 16(7):749–751CrossRefPubMedGoogle Scholar
  31. 31.
    Boyes AW, Girgis A, D’Este C, Zucca AG (2012) Prevalence and correlates of cancer survivors supportive care needs 6 months after diagnosis: a population-based cross-sectional study. BMC Cancer 18(12):150CrossRefGoogle Scholar
  32. 32.
    Park BW, Hwang SY (2012) Unmet needs and their relationship with quality of life among women with recurrent breast cancer. J Breast Cancer 15(4):454–461CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Brennan ME, Butow P, Spillane AJ, Boyle F (2014) Patient-reported quality of life, unmet needs and care coordination outcomes: moving forward targeted breast cancer survivorship care planning. Asia Pac J Clin Oncol. doi: 10.1111/ajco.12254 PubMedGoogle Scholar
  34. 34.
    Cheng KK, Darshini Devi R, Wong WH, Koh C (2014) Perceived symptoms and the supportive care needs of breast cancer survivors 6 months to 5 years post-treatment period. Eur J Oncol Nurs 18(1):3–9CrossRefPubMedGoogle Scholar
  35. 35.
    Bredart A, Merdy O, Sigal-Zafrani B et al (2015) Identifying trajectory clusters in breast cancer survivors’ supportive care needs, psychosocial difficulties, and resources from the completion of primary treatment to 8 months later. Support Care Cancer 24:357–366CrossRefPubMedGoogle Scholar
  36. 36.
    Hodgkinson K, Butow P, Hunt GE et al (2007) Breast cancer survivors’ supportive care needs 2–10 years after diagnosis. Support Care Cancer 15(5):515–523CrossRefPubMedGoogle Scholar
  37. 37.
    2016 Cancer survivorship symposium: advancing care and research. J Clin Oncol 34(3S)Google Scholar
  38. 38.
    Sarfati D, Gurney J, Stanley J et al (2014) Development of a pharmacy-based comorbidity index for patients with cancer. Med Car 52(7):586–593. doi: 10.1097/MLR.0000000000000149 CrossRefGoogle Scholar
  39. 39.
    Rossouw JE, Prentice RL, Manson JE et al (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297(13):1465–1477CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Kathy Pan
    • 1
  • Rowan T. Chlebowski
    • 2
    Email author
  • Michael S. Simon
    • 3
  • Roberta M. Ray
    • 4
  • Jennifer Livaudais-Toman
    • 5
  • Shannon D. Sullivan
    • 6
  • Marcia L. Stefanick
    • 7
  • Robert B. Wallace
    • 8
  • Meryl LeBoff
    • 9
  • Elizabeth Carhart Bluhm
    • 9
  • Electra D. Paskett
    • 10
  1. 1.Harbor-UCLA Medical CenterTorranceUSA
  2. 2.Los Angeles BioMedical Research Institute at Harbor-UCLA Medical CenterTorranceUSA
  3. 3.Karmanos Cancer Institute at Wayne State UniversitDetroitUSA
  4. 4.Fred Hutchinson Cancer Research Center Division of Public Health SciencesSeattleUSA
  5. 5.University of California at San FranciscoSan FranciscoUSA
  6. 6.MedStar Washington Hospital CenterWashingtonUSA
  7. 7.Stanford Prevention Research CenterStanfordUSA
  8. 8.University of Iowa College of Public HealthIowa CityUSA
  9. 9.Brigham and Women’s HospitalBoston Harvard Medical SchoolBostonUSA
  10. 10.The Ohio State University Comprehensive Cancer CenterColumbusUSA

Personalised recommendations